Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.40737 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Lina Renkhold und 13 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Dermatology, University Hospital Münster, Münster, Germany; Center for Chronic Pruritus, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Pruritus, Psoriasis, Antibodies, Monoclonal, Humanized, Skin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The occurrence of pruritus in psoriasis was previously underestimated but is a significant burden. Secukinumab (SEC), a monoclonal anti-interleukin-17A antibody, efficiently controls signs of psoriasis, but the effect on pruritus and cutaneous neuroanatomy remained unknown. The primary objective of this study (NCT02362789) was to evaluate the superiority of SEC treatment vs placebo on pruritus intensity (visual analogue scale; VAS). Furthermore, the treatment-dependent course of pruritus in association with absolute Psoriasis Area Severity Index (PASI) score, as well as cutaneous histopathology and neuroanatomy, was assessed. Open-label SEC 300 mg s.c. was administered regularly until week 16. Patients who reached a ≥ 98% PASI reduction (PASI ≥ 98) were randomized to receive either placebo or SEC up to week 32. Punch biopsies were collected from lesional psoriatic (baseline, weeks 16 and 32) and non-lesional (baseline) skin for histopathological and neuroanatomical analyses. VAS scores improved significantly after open-label SEC treatment but relapsed upon placebo (29.92 ± 33.8) compared with SEC (12.30 ± 22.6; p = 0.036). After SEC-dependent improvement in PASI, histopathology, marker expression and neuroanatomy, relapse was observed with treatment discontinuation in all parameters except neuroanatomy. SEC was superior to placebo by efficiently controlling reduced pruritus intensity, clinically normalizing skin lesions, and reversing histopathological abnormalities. The neuroanatomy recovered upon SEC and remained stable even after withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Dermatology, University Hospital Münster, Münster, Germany; Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.
- Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Tra…
- Institute of Immunology, University of Oldenburg, Oldenburg, Germany.
- Department of Dermatology, University Hospital Münster, Münster, Germany.
- Novartis Pharma GmbH, Nuremberg, Germany.
- Novartis Pharma AG, Basel, Switzerland.
ORCID-Profile: Lina Renkhold, Manuel P Pereira, Karin Loser, Daniel Baeumer, Athanasios Tsianakas, Thomas Luger, Christian Mess, Konstantin Agelopoulos, Sonja Ständer
Zitieren
APA
Renkhold, L., Pereira, M. P., Loser, K., Metze, D., Baeumer, D., Melzer, N., Reinhardt, M., Tsianakas, A., Luger, T., Mess, C., Becker, R., Hambüchen, C., Agelopoulos, K., & Ständer, S. (2024). Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.40737
Vancouver
Renkhold L, Pereira MP, Loser K, Metze D, Baeumer D, Melzer N, et al. Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.40737
BibTeX
@article{Renkhold2024,
author = {Renkhold, Lina and Pereira, Manuel P and Loser, Karin and Metze, Dieter and Baeumer, Daniel and Melzer, Nima and Reinhardt, Maximilian and Tsianakas, Athanasios and Luger, Thomas and Mess, Christian and Becker, Ruth and Hambüchen, Clara and Agelopoulos, Konstantin and Ständer, Sonja},
title = {Secukinumab Reduces Psoriasis-associated Pruritus and Regenerates the Cutaneous Nerve Architecture: Results from PSORITUS a Doubleblind, Placebo-controlled, Randomized Withdrawal Phase IIIb Study},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.40737}
}
EUVIMED